CD33Bi FPBMC (University Of Virginia)

N/A

Report date: 2026/05/12 20:00:17

Base Information

Drug NameCD33Bi FPBMC (University Of Virginia)

Drug Alias Nameanti-CD3 x anti-CD33 bispecific antibody (CD33Bi) armed fresh peripheral blood mononuclear cells (University Of Virginia)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Leukocyte cell therapy > Monocyte cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-Myeloid cell surface antigen CD33Anti-CD3

TargetsMyeloid cell surface antigen CD33T cell surface glycoprotein CD3

Therapy Area/IndicationsMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative DiseasesLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Virginia

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Virginia

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative DiseasesLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A